摘要
Urothelial carcinoma(UC)is the 9th most common and the 13th most deadly cancer worldwide1.Despite the availability of platinum-based chemotherapy and immune checkpoint inhib-itors(ICIs),the 5-year survival rate of patients with metastatic UC(mUC)remains poor(10-15%)2.
基金
supported by the Beijing Natural Science Foundation(Grant No.L244024)
National Natural Science Foundation of China(Grant Nos.82172604 and 82473199)
CSCO Clinical Oncology Research Foundation(Grant No.Y-2022HER2AZMS-0258).
